Dr. Yi-Yen Chen has over 10 years of experience in the life sciences industry. She currently works at PCI Ventures, focusing on venture creation and portfolio management. Previously, she held positions at Echo Investment Capital, overseeing life sciences investments, and at Microbio Group in Taiwan, working in business development and drug licensing. At GeneTex, Dr. Chen led the development of the world’s largest antibody portfolio for zebrafish research. She completed her PhD in developmental biology at the Max-Planck Institute in Germany, under Nobel Laureate Professor Christiane Nüsslein-Volhard. Her postdoctoral training includes molecular biology at the Institute of Molecular Biology in Mainz, Germany, and cancer immunotherapy at the Netherlands Cancer Institute in Amsterdam.
